CDT Equity Issues $541K Convertible Note and Amends Sarborg Deal, Adding Warrants and Share-Based Consideration
CDT is trading near its 52-week low of $0.612 (1.6% above the low).
Summary
CDT Equity issued a $541,620 convertible note to J.J. Astor & Co. with 237,000 warrants, and amended its Sarborg deal to pay $1.75M of the $8M consideration in stock. The note was repaid in full on September 4, 2026, but warrants and ATM-based payment obligations remain.
Key Events · Financing and Capital Events · CDT
-
New $541,620 Convertible Note Issued
CDT Equity issued a senior secured convertible note to J.J. Astor & Co. on August 31, 2026, with $401,200 funded and net proceeds of $375,002. The note was repaid in full on September 4, 2026.
-
237,000 Warrants at $1.69 Exercise Price
The company issued 237,000 common stock purchase warrants to J.J. Astor & Co., exercisable immediately at $1.69 per share, expiring five years from issuance. The warrants remain outstanding after the note repayment.
-
Sarborg Amendment: $1.75M Paid in Stock
CDT amended its Sarborg Limited agreement to satisfy $1,750,000 of the $8,000,000 cash consideration via issuance of 650,000 shares (issued August 31, 2026). Remaining $5,500,000 is payable from ATM proceeds at $150,000/month minimum, due by May 31, 2027.
-
Floor Price Reset to $0.338
The conversion floor price for both the new note and the existing J.J. Astor note was reset to $0.338, with future resets every six months beginning December 11, 2026, based on 20% of the lowest VWAP over the preceding 20 trading days.
Analysis · CDT · Life Sciences
CDT Equity continues its pattern of highly dilutive, survival-driven financing. The new $541,620 senior secured convertible note to J.J. Astor & Co. carries a 70%-of-VWAP conversion discount with a $0.338 floor price, plus 237,000 warrants at $1.69 — terms that heavily favor the lender. The Sarborg amendment converts $1.75M of cash consideration into 650,000 shares, reducing immediate cash outlay but adding dilution. The note was repaid in full on September 4, 2026, but the warrants remain outstanding and exercisable, and the ATM program is now obligated to fund $150,000/month to Sarborg through May 2027. Against a backdrop of $747K cash, a going concern warning, and a stock trading near its 52-week low, this filing shows the company is still relying on expensive, dilutive capital to stay afloat.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDT was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $491.7K. The 52-week trading range was $0.61 to $2,440.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.